Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Redox Rep. 2010;15(2):50-63. doi: 10.1179/174329210X12650506623401.
Elevated reactive oxygen species (ROS) formation in the vascular wall is a key feature of cardiovascular diseases and a likely contributor to oxidative stress, endothelial dysfunction and vascular inflammation. The NADPH oxidases are a family of ROS generating enzymes, of which four members (Nox1, Nox2, Nox4 and Nox5) are expressed in blood vessels. Numerous studies have demonstrated that expression and activity of at least two isoforms of NADPH oxidase - Nox1 and Nox2 - are up-regulated in animal models of hypertension, diabetes and atherosclerosis. However, these observations are merely suggestive of a role for NADPH oxidases in vessel pathology and by no means establish cause and effect. Furthermore, questions surrounding the specificity of current pharmacological inhibitors of NADPH oxidase mean that findings obtained with these compounds must be viewed with caution. Here, we review the literature on studies utilising genetically-modified mouse strains to investigate the roles of NADPH oxidases in experimental models of vascular disease. While several studies on transgenic over-expressing or knockout mice support roles for Nox1- and/or Nox2-containing oxidases as sources of excessive vascular ROS production and causes of endothelial dysfunction in hypertension, atherosclerosis and diabetes, there are still no published reports on the effects of genetic modification of Nox4 or Nox5 in vascular or indeed any other contexts. Further understanding of the roles of specific isoforms of NADPH oxidase in vascular (patho)physiology should provide direction for future programs aimed at developing selective inhibitors of these enzymes as novel therapeutics in cardiovascular disease.
血管壁中活性氧(ROS)的生成增加是心血管疾病的一个关键特征,也是氧化应激、内皮功能障碍和血管炎症的一个可能原因。NADPH 氧化酶是一类 ROS 生成酶,其中 4 个成员(Nox1、Nox2、Nox4 和 Nox5)在血管中表达。许多研究表明,至少两种 NADPH 氧化酶同工型(Nox1 和 Nox2)的表达和活性在高血压、糖尿病和动脉粥样硬化的动物模型中上调。然而,这些观察结果仅仅表明 NADPH 氧化酶在血管病变中的作用,绝不能确定其因果关系。此外,围绕 NADPH 氧化酶的当前药理学抑制剂的特异性的问题意味着,必须谨慎看待这些化合物获得的研究结果。在这里,我们综述了利用基因修饰小鼠模型研究 NADPH 氧化酶在血管疾病实验模型中的作用的文献。虽然几项关于转基因过表达或敲除小鼠的研究支持 Nox1-和/或 Nox2 包含的氧化酶作为高血压、动脉粥样硬化和糖尿病中血管 ROS 过度产生的来源和内皮功能障碍的原因的作用,但仍没有关于 Nox4 或 Nox5 基因修饰在血管或其他任何情况下的影响的报道。进一步了解 NADPH 氧化酶特定同工型在血管(病理)生理学中的作用,应该为未来旨在开发这些酶的选择性抑制剂作为心血管疾病新疗法的项目提供方向。